Translate this page into:
When Symptoms become Vital Signs…. Fetch your End-of-Life Care Crash Cart
*Corresponding author: Megha Pruthi, Department of Pain and Palliative Medicine, Fortis Memorial Research Institute, Gurgaon, Haryana, India. dr.meghapruthi@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Pruthi M, Chanana G. When Symptoms become Vital Signs…. Fetch your End-of-Life Care Crash Cart. Indian J Palliat Care. 2026;32:111-3. doi: 10.25259/IJPC_231_2025
Dear Editor,
As Tagore poignantly expressed, ‘Death is not extinguishing the light; it is only putting out the lamp because the dawn has come’.[1] This timeless perspective invites us to reframe our approach to dying – not as a failure of medicine, but as a natural and meaningful part of life’s journey.
By gradually moving beyond the traditional biomedical model – which often emphasises cure alone – we have an opportunity to transform hospitals into healing environments where quality of life, dignity and comfort are prioritised in the terminal phase.[2] Shifting the focus from aggressive physiological monitoring to attentive monitoring for the discomforting symptoms and signs of distress allows us to better meet the physical, emotional and spiritual needs of patients and their families during this profound time.
Yet, this shift in perspective remains elusive within the healthcare community, particularly in acute care settings, where most patients with chronic, life-limiting illnesses spend their final days.[3,4] Encouragingly, the 2023 Supreme Court of India judgment, which granted legal validity to advance medical directives and simplified the process of withholding or withdrawing life-sustaining treatment, marks a crucial milestone in the country’s end-of-life care landscape.[5] With this legal clarity, hospital-based endof-life care is likely to increase, necessitating a parallel strengthening of institutional preparedness, healthcare provider education and the availability of essential resources.
Once the dying phase is identified, this must be followed by proactive assessment and management of symptoms by a multidisciplinary team. During this phase, healthcare providers must anticipate distress, rather than wait for patients or families to report symptoms. Literature describes over 55 symptoms that may manifest at the end of life, many of which are underrecognised and poorly managed, particularly in imminently dying patients.[6] Common distressing issues include pain, anorexia-cachexia, delirium, nausea, vomiting, dyspnoea, constipation and asthenia, among others.[6]
The hospital’s end-of-life care (EOLC) policy must contain an EOLC symptom monitoring chart. An example that is being used in our hospital is attached, as shown in Figure 1.

- End-of-life care monitoring. IV: Intravenous.
We propose the implementation of an ‘End-of-Life Care (EOLC) Crash Cart’ [Table 1], a structured and easily accessible resource that includes anticipatory prescriptions and essential pharmacological agents tailored to manage the most common and distressing symptoms in the terminal phase of illness.[7,8] The cart should be easily available for ready use once a patient is on end-of-life care (just like an Emergency Crash cart for Code Blue). The cart may be individualised through team discussions whenever required. Its availability would ensure timely symptom control, minimise unnecessary delays in medication administration and foster a sense of preparedness within the care team.
| Symptom | Drug | Formulation/strength | Recommended dose |
|---|---|---|---|
| Pain/Dyspnoea | Morphine | Oral IR Tablet 10 mg; Injection 15 mg/mL | Oral: 2.5–10 mg q4 h; IV/SC: 1–3 mg q1h PRN or continuous infusion |
| Fentanyl | Injection 50 mcg/mL; OTFC 200 mcg | IV/SC: 25–50 mcg q1 h PRN; OTFC: 200 mcg for breakthrough pain (opioid-tolerant only) | |
| Acetaminophen | Tablet 500 mg, 650 mg; Injection 1 g/100 mL | Oral/IV: 500–1,000 mg q6–8 h (max 4 g/day) | |
| Dexamethasone | Tablet 0.5 mg, 4 mg; Injection 4 mg/mL | Oral/IV/SC: 4–16 mg/day (divided) for pain, raised ICP, dyspnoea, fatigue | |
| Hydrocortisone | Injection 100 mg/vial | IV: 25–100 mg q6–8 h (as an adjuvant in dyspnoea) | |
| Delirium/Nausea | Haloperidol | Tablet 0.5 mg, 5 mg; Injection 5 mg/mL | Oral: 0.5–2 mg q8–12 h; SC/IV: 0.5–2 mg q4–6 h PRN (max 10 mg/day) |
| Quetiapine | Tablet 12.5 mg, 25 mg | Oral: 12.5–50 mg q12 h | |
| Olanzapine | Tablet 2.5 mg, 5 mg | Oral: 2.5–10 mg at night (max 20 mg/day) | |
| Metoclopramide | Tablet 10 mg; Injection 5 mg/mL | Oral/IV/SC: 10 mg q6–8 h (max 40 mg/day) | |
| Insomnia/anxiety/seizure | Midazolam | Injection 5 mg/5 mL; Nasal Spray 0.5 mg/puff | SC/IV: 2.5–5 mg q2–4h PRN; CI: 0.5–2 mg/h; Nasal: 2.5–5 mg |
| Lorazepam | Tablet 0.5–1 mg; Injection 1 mg/mL | Oral/SL: 0.5–2 mg q6–8h PRN; IV: 2–4 mg for seizure (may repeat) | |
| Respiratory/GI secretions | Glycopyrrolate | Tablet 1–2 mg; Injection 0.2 mg/mL | Oral: 1–2 mg q6–8h; SC/IV: 0.2–0.4 mg q4–6 h PRN (max 1.2 mg/day) |
| Hyoscine butylbromide | Tablet 10 mg; Injection 10 mg/mL | Oral/SC/IV: 20 mg q6–8 h (max 120 mg/day) | |
| Constipation | Milk of magnesia/liquid paraffin | Syrup | Oral: 10–30 mL once daily |
| Lactulose | Syrup 10 g/15 mL | Oral: 15–30 mL once or twice daily (titrate to effect) | |
| Bisacodyl | Tablet 5 mg; Suppository 5 mg | Oral: 5–10 mg HS; Rectal: 10 mg once daily | |
| Cough | Linctus codeine | Syrup 10 mg/5 mL | Oral: 10–20 mg q6h PRN (max 120 mg/day) |
| Gastritis/GI protection | Pantoprazole | Tablet 40 mg; Injection 40 mg/vial | Oral/IV: 40 mg OD–BD |
| Cardiac failure/oedema | Furosemide | Injection 40 mg/4 mL | IV: 20–40 mg once, repeat PRN (may double dose if resistant) |
| Opioid toxicity/overdose | Naloxone | Injection 0.4 mg/mL | IV: 0.1–0.2 mg q2–3 min PRN until reversal; infusion may be needed |
IR: Immediate relief, PRN: As and when required, OTFC: Oral transmucosal fentanyl citrate, ICP: Intracranial pressure, CI: Continuous infusion, GI: Gastrointestinal. For patients who are not able to swallow and do not have an IV access, subcutaneous/rectal/sublingual (oral tablets crushed and made into a paste with small amounts of water) can be used as an alternate route.
Such a system can significantly enhance the confidence and clinical autonomy of nurses and other frontline healthcare providers, enabling them to respond swiftly and appropriately to evolving symptom burdens. Empowering the team in this way not only improves patient comfort but also reduces the moral distress associated with witnessing suffering that could otherwise be mitigated. However, this pharmacological readiness must be complemented by non-pharmacological interventions grounded in communication, compassion and collaborative care.
Ethical approval:
The Institutional Review Board approval is not required.
Declaration of patient consent:
Patient’s consent was not required as there are no patients in this study.
Conflicts of interest:
Dr.Gaurav Chanana is on the Editorial Board of the journal.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation:
The authors confirm that they have used artificial intelligence (AI)-assisted technology solely for language refinement and to improve the clarity of writing. No AI assistance was employed in the generation of scientific content, data analysis or interpretation.
Financial support and sponsorship: Nil.
References
- Models of delivering palliative and end-of-life care in India. Curr Opin Support Palliat Care. 2013;7:216-22.
- [CrossRef] [PubMed] [Google Scholar]
- The escalating global burden of serious health-related suffering: Projections to 2060 by world regions, age groups, and health conditions. Lancet Glob Health. 2019;7:e883-92.
- [CrossRef] [PubMed] [Google Scholar]
- Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: The lancet commission report. Lancet. 2018;391:1391-454.
- [CrossRef] [PubMed] [Google Scholar]
- Common Cause (A Regd Society) vs Union of India. Available from https://indiankanoon.org/doc/184449972 [Last accessed on 2025 May 29]
- [Google Scholar]
- Symptom expression in the last seven days of life among cancer patients admitted to acute palliative care units. J Pain Symptom Manage. 2015;50:488-94.
- [CrossRef] [PubMed] [Google Scholar]